-
公开(公告)号：US20160074366A1
公开(公告)日：2016-03-17
申请号：US14950571
申请日：2015-11-24
IPC分类号： A61K31/4178 , A61K9/16 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。
-
公开(公告)号：US20170143677A1
公开(公告)日：2017-05-25
申请号：US15406237
申请日：2017-01-13
IPC分类号： A61K31/4178 , A61K9/10 , A61K9/19 , A61K9/16 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
-
公开(公告)号：US20210015796A1
公开(公告)日：2021-01-21
申请号：US17064693
申请日：2020-10-07
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
-
公开(公告)号：US20160243083A1
公开(公告)日：2016-08-25
申请号：US15144124
申请日：2016-05-02
IPC分类号： A61K31/4178 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
-
公开(公告)号：US20180125822A1
公开(公告)日：2018-05-10
申请号：US15865404
申请日：2018-01-09
IPC分类号： A61K31/4178 , A61K9/19 , A61K9/16 , A61K9/00 , A61K9/10
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
-
6.发明申请Treatment Methods with Low-Dose, Longer-Acting Formulations of Local Anesthetics and Other Agents 审中-公开低剂量，局部麻醉剂及其他药剂长效配方的治疗方法公开(公告)号：US20140105989A1
公开(公告)日：2014-04-17
申请号：US14138279
申请日：2013-12-23
IPC分类号： A61K31/445 , A61K9/14
CPC分类号： A61K9/141 , A61K9/1274 , A61K31/00 , A61K31/24 , A61K31/445 , A61K47/10 , A61K47/18
摘要： Drug formulations that provide sustained action and/or reduced dosage requirements are provided. In the formulations the drugs (particularly local anesthetics) are associated with reversed cubic phase and reversed hexagonal phase lyotropic liquid crystalline material.
摘要翻译： 提供了提供持续作用和/或降低剂量要求的药物制剂。 在制剂中，药物（特别是局部麻醉剂）与反相立方相和反相六方相溶致液晶材料相关。
-
公开(公告)号：US20140099382A1
公开(公告)日：2014-04-10
申请号：US14103546
申请日：2013-12-11
IPC分类号： A61K31/4178
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译： 提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。 一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。 丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术 涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
